[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369748-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369748-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-pan-cancer-comparative-analysis-of-the-cancer-genome-atlas-transcriptomic-til-immune-signatures","A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures","","A pan-cancer comparison evaluates transcriptomic tumor-infiltrating lymphocyte (TIL) immune signatures derived from cancer genome atlas (TCGA) analyses, addressing a gap where no prior study benchmarked their prognostic value across tumor types. A library of 146 TIL-immune signatures is scored for correlation with overall survival (OS) and progression-free interval (PFI) using 9,961 TCGA samples spanning 33 tumor types. Zhang CD8 TCS shows higher prognostic accuracy overall, with variability by cancer type and germ cell origin.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-pan-cancer-comparative-analysis-of-the-cancer-genome-atlas-transcriptomic-til-immune-signatures/369748/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-pan-cancer-comparative-analysis-of-the-cancer-genome-atlas-transcriptomic-til-immune-signatures/369748.png","ImageObject",300,407,{"name":42,"@type":43},"eBook King","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address about TIL-immune signatures?","Question",{"text":63,"@type":64},"It addresses the lack of pan-cancer analysis comparing how TIL-immune signatures perform prognostically across tumor types using OS and PFI as endpoints.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many TCGA samples and tumor types are included in the evaluation?",{"text":68,"@type":64},"The evaluation uses 9,961 available TCGA samples across 33 tumor types.",{"name":70,"@type":61,"acceptedAnswer":71},"Which TIL-immune signature shows the best prognostic performance overall?",{"text":72,"@type":64},"Zhang CD8 TCS demonstrates higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape, though performance varies by cancer type and germ cell origin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369748,1790228909,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Cancer Immunology, Immunotherapy (2025) 74:286 [https://doi.org/10.1007/s00262-025-04102-3](https://doi.org/10.1007/s00262-025-04102-3)  \nA pan‑cancer comparative analysis of the cancer genome atlas transcriptomic TIL‑immune signatures  \nKyle J. Hitscherich1 · Darryl Nousome2,3 · Aaron J. Dinerman1 · Victoria Dulemba1 · Frank J. Lowery1 · Naris Nilubol4  \nReceived: 13 April 2025 / Accepted: 30 May 2025 / Published online: 7 August 2025  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025  \nAbstract  \nEfforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL) . However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints. We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin. Cluster analysis compiled a group of six signatures (Oh.Cd8 . MAIT, Grog.8KLRB1, Oh.TIL_CD4.GZMK, Grog.CD4.TCF7, Oh.CD8.RPL, Grog.CD4.RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.  \nKeywords Cancer · Immunotherapy · Single cell sequencing · Tumor microenvironment · Tumor-infiltrating lymphocytes  \nIntroduction  \nThe cancer genome atlas (TCGA) program curated multiomic data, clinical characteristics, and outcomes of over 10,000 primary cancers from 33 cancer types over the past 17 years [1] . The goal of the project evolved from understanding the genetics of a select cancer histology,(glioblastoma multiforme) to now using combined tumor and microenvironment transcriptomics to better understand cancer biology as it relates to outcomes [1] .  \n* Kyle J. Hitscherich [kylehitsche@gmail.com](kylehitsche@gmail.com)  \n* Naris Nilubol [naris.nilubol@nih.gov](naris.nilubol@nih.gov)  \n1 Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD 20878, USA  \n2 CCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA  \n3 Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA  \n4 Endocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD, USA  \nImmunotherapy has evolved over the past two decades asa promising arm of cancer therapy that can provide robust and durable responses for a wide variety of cancer types [2]. As success with checkpoint inhibitors (anti-PD-1, -PDL1, -CTLA-4) and adoptive cell transfer (ACT, including chimeric antigen receptor (CAR) and tumor-infiltrating lymphocyte (TIL)) becomes more prevalent, the interest in the regulation of the immune system in the tumor microenvironment (TME) has grown. [3–7] Multiple immune gene signatures have been developed from transcriptomic data looking to better describe TIL populations and how they may impact the TME [8–11] . Several of these in-depth evaluations of the tumor-immune microenvironment have sought to identify populations ofT-cells that may be associated with disease progression through cytotoxic function, neoantigen recognition, or a more “stem-like” phenotypic state in specific tumors [7] .  \nIn querying the TCGA, numerous research teams have sought to incorporate patient outcomes data into the development of predictive gene signatures. [12–17] In many instances, these signatures include similar genes compared to those constructed from direct pa","cbCaigZPURxLFjXe","https://ap.wps.com/l/cbCaigZPURxLFjXe","pdf",1755042,16,"English","# Abstract\n# Introduction\n# Methods\n## Gene signature library construction and sample accrual","[{\"question\":\"What problem does the study address about TIL-immune signatures?\",\"answer\":\"It addresses the lack of pan-cancer analysis comparing how TIL-immune signatures perform prognostically across tumor types using OS and PFI as endpoints.\"},{\"question\":\"How many TCGA samples and tumor types are included in the evaluation?\",\"answer\":\"The evaluation uses 9,961 available TCGA samples across 33 tumor types.\"},{\"question\":\"Which TIL-immune signature shows the best prognostic performance overall?\",\"answer\":\"Zhang CD8 TCS demonstrates higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape, though performance varies by cancer type and germ cell origin.\"}]","A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures | PDF",1790184335,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a336dba5e5f925a0bfc1ab51d481b801.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/317169b56de622c63d17c9d5240f73e4.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20afcf79c5fae1773c50d2b98ea72a43.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28f1ad9c0ab0df456f049fa3544ccccf.webp",980,1301]